ATE489624T1 - Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose - Google Patents

Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose

Info

Publication number
ATE489624T1
ATE489624T1 AT06752069T AT06752069T ATE489624T1 AT E489624 T1 ATE489624 T1 AT E489624T1 AT 06752069 T AT06752069 T AT 06752069T AT 06752069 T AT06752069 T AT 06752069T AT E489624 T1 ATE489624 T1 AT E489624T1
Authority
AT
Austria
Prior art keywords
prognosis
antibodies against
cancer diagnosis
clinical cancer
histone modifications
Prior art date
Application number
AT06752069T
Other languages
English (en)
Inventor
Siavash K Kurdistani
Michael Grunstein
David B Seligson
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE489624T1 publication Critical patent/ATE489624T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06752069T 2005-04-29 2006-05-01 Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose ATE489624T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67602105P 2005-04-29 2005-04-29
US77823506P 2006-03-01 2006-03-01
PCT/US2006/016765 WO2006119264A2 (en) 2005-04-29 2006-05-01 Antibodies against histone modifications for clinical diagnosis and prognosis of cancer

Publications (1)

Publication Number Publication Date
ATE489624T1 true ATE489624T1 (de) 2010-12-15

Family

ID=37308614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06752069T ATE489624T1 (de) 2005-04-29 2006-05-01 Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose

Country Status (6)

Country Link
US (1) US20080248039A1 (de)
EP (2) EP1896849B1 (de)
AT (1) ATE489624T1 (de)
CA (1) CA2607327A1 (de)
DE (1) DE602006018458D1 (de)
WO (1) WO2006119264A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319376D0 (en) 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
US20100151468A1 (en) * 2007-04-11 2010-06-17 Manel Esteller Epigenetic biomarkers for early detection, therapeutic effectiveness, and relapse monitoring of cancer
WO2010120942A2 (en) * 2009-04-14 2010-10-21 The Regents Of The University Of California Histone modification patterns for clinical diagnosis and prognosis of cancer
GB201303576D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers
CN113075408B (zh) * 2021-03-16 2024-08-23 上海市同仁医院 一种利用组蛋白作为内参的免疫组织化学定量方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU2002367838A1 (en) * 2001-05-11 2003-11-11 Stamatoyannopoulos, John A DNA microarrays comprising active chromatin elements and comprehensive profiling therewith
US20040197838A1 (en) * 2001-08-03 2004-10-07 Allis C David Phosphorylated histone h2b as apoptosis marker
JP2005517431A (ja) * 2002-02-20 2005-06-16 ユニバーシティ　オブ　バージニア　パテント　ファウンデーション ヒストン修飾マーカーを利用した非侵襲的診断検査
EP1403639A1 (de) * 2002-09-30 2004-03-31 G2M Cancer Drugs AG Antikörper als Diagnosemittel in der medizinischen Therapie mit Histondeacetylase-Hemmern
GB0319376D0 (en) * 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
WO2006071608A2 (en) * 2004-12-16 2006-07-06 President And Fellows Of Harvard College Histone demethylation mediated by the nuclear amine oxidase homolog lsd1

Also Published As

Publication number Publication date
DE602006018458D1 (de) 2011-01-05
WO2006119264A2 (en) 2006-11-09
EP1896849A2 (de) 2008-03-12
WO2006119264A3 (en) 2006-12-21
EP2267450B1 (de) 2015-01-28
EP2267450A3 (de) 2011-04-13
EP2267450A2 (de) 2010-12-29
EP1896849A4 (de) 2009-01-14
US20080248039A1 (en) 2008-10-09
CA2607327A1 (en) 2006-11-09
EP1896849B1 (de) 2010-11-24

Similar Documents

Publication Publication Date Title
ES2484142T3 (es) Diagnóstico molecular y clasificación del melanoma maligno
ATE534905T1 (de) Cop1-moleküle und verwendungen davon
EA201370063A1 (ru) Фосфолипидом рака
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
BRPI0720371B8 (pt) métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata
DK1889059T3 (da) Fremgangsmåde til forbedret immunoassay
ATE490465T1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
ATE483972T1 (de) Reagenzien und verfahren für krebsprognose und pathologische einstufung
NO20084546L (no) Diagnostikk og behandlinger for tumorer
WO2007109881A8 (en) Biomarkers useful for diagnosing prostate cancer, and methods thereof
ATE551367T1 (de) Epha2-bindende antikörper und verfahren zu ihrer verwendung
WO2008148072A3 (en) Disease-associated genetic variations and methods for obtaining and using same
WO2010120942A3 (en) Histone modification patterns for clinical diagnosis and prognosis of cancer
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
PL1889067T3 (pl) Aneksyna do oceny ryzyka wystąpienia raka
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
WO2007016367A3 (en) Neoplastic disease-related methods, kits, systems and databases
DE602007007958D1 (de) Antikörper gegen ein epitop auf agr2, assays und hybridome
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
EP4220171A3 (de) Marker für endometriumkrebs
SG165370A1 (en) Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
BRPI0606685A2 (pt) anticorpos gitr para o diagnóstico de nsclc
ATE489624T1 (de) Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
EP1924710A4 (de) Verfahren zur diagnose eines ovarialkarzinoms und kits dafür

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties